AMRN
Amarin Corporation plc
Price Chart
Latest Quote
$13.93
+0.13 (+0.94%)
Current Price
| Previous Close | $13.80 |
| Open | $13.89 |
| Day High | $14.24 |
| Day Low | $13.84 |
| Volume | 160,919 |
Stock Information
| Shares Outstanding | 20.97M |
| Total Debt | $7.70M |
| Cash Equivalents | $307.82M |
| Revenue | $216.76M |
| Net Income | $-33.61M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $292.10M |
| EPS (TTM) | $-1.60 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.54B |
| Sales | $216.76M |
| Income | $-33.61M |
| Book/sh | $21.42 |
| Cash/sh | $14.68 |
| Employees | 80 |
Financial Ratios
| Quick Ratio | 2.31 |
| Current Ratio | 3.48 |
| Debt/Eq | 1.71 |
Returns & Margins
| ROA | -0.50% |
| ROE | -7.28% |
| Gross Margin | 52.36% |
| Operating Margin | -17.75% |
| Profit Margin | -15.51% |
Ownership
| Insider Ownership | 1.97% |
| Institutional Ownership | 22.91% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 14.21 |
| PEG | 0.81 |
| P/S | 1.35 |
| P/B | 0.65 |
Analyst Data
| Recommendation | none |
| Target Price | $12.50 |
Technical Indicators
| SMA20 | $14.48 |
| SMA50 | $14.50 |
| SMA200 | $15.40 |
| RSI | 38.87 |
| ATR | 0.5229 |
| Shares Float | 370.27M |
| Short Float | 3.01% |
| Short Ratio | 7.54 |
| Volatility | 0.82 |
| Rel Volume | 2.58 |
Performance History
| Week | -3.86% |
| Month | -6.51% |
| Quarter | -0.92% |
| 6 Months | -14.49% |
| YTD | +1.53% |
| Year | +17.55% |
| 3 Years | -40.47% |
| 5 Years | -84.66% |
| 10 Years | -69.45% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $13.93 | 161,300 |
| 2026-06-04 | $13.80 | 296,800 |
| 2026-06-03 | $14.53 | 50,700 |
| 2026-06-02 | $14.47 | 65,700 |
| 2026-06-01 | $14.36 | 34,900 |
| 2026-05-29 | $14.49 | 44,800 |
| 2026-05-28 | $14.41 | 44,900 |
| 2026-05-27 | $14.52 | 51,200 |
| 2026-05-26 | $14.30 | 67,000 |
| 2026-05-22 | $14.43 | 35,900 |
| 2026-05-21 | $14.55 | 32,500 |
| 2026-05-20 | $14.27 | 35,500 |
| 2026-05-19 | $14.05 | 31,600 |
| 2026-05-18 | $14.06 | 38,400 |
| 2026-05-15 | $14.56 | 55,900 |
| 2026-05-14 | $14.78 | 44,700 |
| 2026-05-13 | $15.02 | 48,700 |
| 2026-05-12 | $14.95 | 27,700 |
| 2026-05-11 | $15.02 | 37,600 |
| 2026-05-08 | $15.05 | 43,200 |
| 2026-05-07 | $14.84 | 37,100 |
| 2026-05-06 | $14.90 | 60,100 |
About Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
đ° Latest News
Generic drugmakers gain key victory in âskinny labelâ patent case
BioPharma Dive âĸ 2026-06-05T11:51:31Z
Sector Update: Healthcare Stocks Climb Late Afternoon
MT Newswires âĸ 2026-06-04T19:50:07ZUpdate: Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case
MT Newswires âĸ 2026-06-04T17:25:50ZSupreme Court Rules Against Amarin in 'Skinny Label' Patent Case
MT Newswires âĸ 2026-06-04T15:12:50ZEuropean Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
MT Newswires âĸ 2026-05-28T15:14:11ZAmarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN)
InvestorsHub âĸ 2026-05-27T15:24:38Z
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
MT Newswires âĸ 2026-05-26T15:09:15ZHow The Amarin (AMRN) Story Is Shifting With A Refined Fair Value And Outlook
Simply Wall St. âĸ 2026-05-22T02:16:15Z
European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading
MT Newswires âĸ 2026-05-18T15:11:28ZKeros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
Zacks âĸ 2026-05-15T16:08:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $92,778,000 | $147,232,000 | $141,370,000 | $126,709,000 |
| Cost Of Revenue | $92,778,000 | $147,232,000 | $141,370,000 | $126,709,000 |
| Total Revenue | $213,646,000 | $228,614,000 | $306,911,000 | $369,193,000 |
| Operating Revenue | $213,646,000 | $228,614,000 | $306,911,000 | $369,193,000 |
| Expenses | ||||
| Interest Expense | $7,000 | $7,000 | $8,000 | $15,000 |
| Total Expenses | $227,587,000 | $320,411,000 | $363,527,000 | $461,536,000 |
| Other Income Expense | $-32,953,000 | $1,201,000 | $-8,909,000 | $-14,266,000 |
| Other Non Operating Income Expenses | $3,276,000 | $1,201,000 | $2,063,000 | $-740,000 |
| Net Non Operating Interest Income Expense | $10,846,000 | $13,396,000 | $11,855,000 | $2,804,000 |
| Interest Expense Non Operating | $7,000 | $7,000 | $8,000 | $15,000 |
| Operating Expense | $134,809,000 | $173,179,000 | $222,157,000 | $334,827,000 |
| Selling And Marketing Expense | $40,592,000 | $79,587,000 | $111,326,000 | $185,614,000 |
| General And Administrative Expense | $74,411,000 | $72,723,000 | $88,612,000 | $118,802,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-38,798,000 | $-82,183,000 | $-59,112,000 | $-105,803,000 |
| Net Interest Income | $10,846,000 | $13,396,000 | $11,855,000 | $2,804,000 |
| Interest Income | $10,853,000 | $13,403,000 | $11,863,000 | $2,819,000 |
| Normalized Income | $-10,177,090 | $-82,183,000 | $-50,444,120 | $-95,117,460 |
| Net Income From Continuing And Discontinued Operation | $-38,798,000 | $-82,183,000 | $-59,112,000 | $-105,803,000 |
| Total Operating Income As Reported | $-50,170,000 | $-91,797,000 | $-67,588,000 | $-105,869,000 |
| Net Income Common Stockholders | $-38,798,000 | $-82,183,000 | $-59,112,000 | $-105,803,000 |
| Net Income | $-38,798,000 | $-82,183,000 | $-59,112,000 | $-105,803,000 |
| Net Income Including Noncontrolling Interests | $-38,798,000 | $-82,183,000 | $-59,112,000 | $-105,803,000 |
| Net Income Continuous Operations | $-38,798,000 | $-82,183,000 | $-59,112,000 | $-105,803,000 |
| Pretax Income | $-36,048,000 | $-77,200,000 | $-53,670,000 | $-103,805,000 |
| Special Income Charges | $-36,229,000 | $0 | $-10,972,000 | $-13,526,000 |
| Interest Income Non Operating | $10,853,000 | $13,403,000 | $11,863,000 | $2,819,000 |
| Operating Income | $-13,941,000 | $-91,797,000 | $-56,616,000 | $-92,343,000 |
| Gross Profit | $120,868,000 | $81,382,000 | $165,541,000 | $242,484,000 |
| Per Share | ||||
| Diluted EPS | $-1.80 | $-4.00 | $-3.00 | $-5.20 |
| Basic EPS | $-1.80 | $-4.00 | $-3.00 | $-5.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $-7,608,090 | $0 | $-2,304,120 | $-2,840,460 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $3,216,000 | $-74,180,000 | $-39,725,000 | $-87,168,000 |
| Total Unusual Items | $-36,229,000 | $0 | $-10,972,000 | $-13,526,000 |
| Total Unusual Items Excluding Goodwill | $-36,229,000 | $0 | $-10,972,000 | $-13,526,000 |
| Reconciled Depreciation | $3,028,000 | $3,013,000 | $2,965,000 | $3,096,000 |
| EBITDA (Bullshit earnings) | $-33,013,000 | $-74,180,000 | $-50,697,000 | $-100,694,000 |
| EBIT | $-36,041,000 | $-77,193,000 | $-53,662,000 | $-103,790,000 |
| Diluted Average Shares | $20,749,200 | $20,546,850 | $20,382,750 | $20,057,750 |
| Basic Average Shares | $20,749,200 | $20,546,850 | $20,382,750 | $20,057,750 |
| Diluted NI Availto Com Stockholders | $-38,798,000 | $-82,183,000 | $-59,112,000 | $-105,803,000 |
| Tax Provision | $2,750,000 | $4,983,000 | $5,442,000 | $1,998,000 |
| Restructuring And Mergern Acquisition | $36,229,000 | $0 | $10,972,000 | $13,526,000 |
| Research And Development | $19,806,000 | $20,869,000 | $22,219,000 | $30,411,000 |
| Selling General And Administration | $115,003,000 | $152,310,000 | $199,938,000 | $304,416,000 |
| Other Gand A | $65,167,000 | $58,557,000 | $76,119,000 | $96,462,000 |
| Salaries And Wages | $9,244,000 | $14,166,000 | $12,493,000 | $22,340,000 |
Fetched: 2026-06-01
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $445,916,000 | $469,787,000 | $532,793,000 | $573,553,000 |
| Total Assets | $670,775,000 | $685,349,000 | $831,684,000 | $886,179,000 |
| Total Non Current Assets | $20,893,000 | $89,950,000 | $106,703,000 | $197,081,000 |
| Other Non Current Assets | $1,055,000 | $65,953,000 | $78,975,000 | $164,078,000 |
| Goodwill And Other Intangible Assets | $13,365,000 | $16,389,000 | $19,304,000 | $21,780,000 |
| Other Intangible Assets | $13,365,000 | $16,389,000 | $19,304,000 | $21,780,000 |
| Current Assets | $649,882,000 | $595,399,000 | $724,981,000 | $689,098,000 |
| Other Current Assets | $24,350,000 | $12,552,000 | $11,618,000 | $19,492,000 |
| Restricted Cash | $201,000 | $300,000 | $525,000 | $523,000 |
| Inventory | $195,910,000 | $166,048,000 | $258,616,000 | $228,732,000 |
| Receivables | $126,832,000 | $122,279,000 | $133,563,000 | $130,990,000 |
| Accounts Receivable | $126,832,000 | $122,279,000 | $133,563,000 | $130,990,000 |
| Allowance For Doubtful Accounts Receivable | $-18,151,000 | $-10,793,000 | $-27,123,000 | $-56,428,000 |
| Gross Accounts Receivable | $144,983,000 | $133,072,000 | $160,686,000 | $187,418,000 |
| Cash Cash Equivalents And Short Term Investments | $302,589,000 | $294,220,000 | $320,659,000 | $309,361,000 |
| Cash And Cash Equivalents | $134,660,000 | $121,038,000 | $199,252,000 | $217,666,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $6,080,000 | $7,723,000 | $8,737,000 | $10,015,000 |
| Long Term Debt And Capital Lease Obligation | $6,080,000 | $7,723,000 | $8,737,000 | $10,015,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $211,494,000 | $199,173,000 | $279,587,000 | $290,846,000 |
| Total Non Current Liabilities Net Minority Interest | $17,035,000 | $19,224,000 | $20,310,000 | $31,367,000 |
| Other Non Current Liabilities | $10,955,000 | $11,501,000 | $9,064,000 | $8,205,000 |
| Current Liabilities | $194,459,000 | $179,949,000 | $259,277,000 | $259,479,000 |
| Other Current Liabilities | $18,338,000 | $17,545,000 | $23,022,000 | $35,643,000 |
| Payables And Accrued Expenses | $176,121,000 | $162,404,000 | $233,914,000 | $221,637,000 |
| Payables | $45,355,000 | $40,366,000 | $52,762,000 | $64,602,000 |
| Accounts Payable | $45,355,000 | $40,366,000 | $52,762,000 | $64,602,000 |
| Non Current Deferred Liabilities | - | $0 | $2,509,000 | $13,147,000 |
| Current Deferred Liabilities | - | $0 | $2,341,000 | $2,199,000 |
| Equity | ||||
| Common Stock Equity | $459,281,000 | $486,176,000 | $552,097,000 | $595,333,000 |
| Total Equity Gross Minority Interest | $459,281,000 | $486,176,000 | $552,097,000 | $595,333,000 |
| Stockholders Equity | $459,281,000 | $486,176,000 | $552,097,000 | $595,333,000 |
| Retained Earnings | $-1,707,344,000 | $-1,668,546,000 | $-1,586,363,000 | $-1,527,251,000 |
| Other | ||||
| Treasury Shares Number | $13,633,477 | $10,672,049 | $9,317,202 | $7,986,831 |
| Ordinary Shares Number | $416,214,102 | $411,584,851 | $408,824,093 | $404,346,256 |
| Share Issued | $429,847,579 | $422,256,900 | $418,141,295 | $412,333,087 |
| Tangible Book Value | $445,916,000 | $469,787,000 | $532,793,000 | $573,553,000 |
| Invested Capital | $459,281,000 | $486,176,000 | $552,097,000 | $595,333,000 |
| Working Capital | $455,423,000 | $415,450,000 | $465,704,000 | $429,619,000 |
| Capital Lease Obligations | $6,080,000 | $7,723,000 | $8,737,000 | $10,015,000 |
| Total Capitalization | $459,281,000 | $486,176,000 | $552,097,000 | $595,333,000 |
| Treasury Stock | $67,360,000 | $65,326,000 | $63,752,000 | $61,770,000 |
| Additional Paid In Capital | $1,923,801,000 | $1,914,750,000 | $1,899,456,000 | $1,885,352,000 |
| Capital Stock | $310,184,000 | $305,298,000 | $302,756,000 | $299,002,000 |
| Common Stock | $310,184,000 | $305,298,000 | $302,756,000 | $299,002,000 |
| Long Term Capital Lease Obligation | $6,080,000 | $7,723,000 | $8,737,000 | $10,015,000 |
| Current Accrued Expenses | $130,766,000 | $122,038,000 | $181,152,000 | $157,035,000 |
| Net PPE | $6,473,000 | $7,608,000 | $8,424,000 | $9,948,000 |
| Accumulated Depreciation | $-1,474,000 | $-1,470,000 | $-1,379,000 | $-2,472,000 |
| Gross PPE | $7,947,000 | $9,078,000 | $9,803,000 | $12,420,000 |
| Leases | $217,000 | $217,000 | $217,000 | $869,000 |
| Other Properties | $6,461,000 | $7,592,000 | $8,310,000 | $9,074,000 |
| Machinery Furniture Equipment | $1,269,000 | $1,269,000 | $1,276,000 | $2,477,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $75,418,000 | - | - | - |
| Work In Process | $8,201,000 | - | - | - |
| Raw Materials | $112,291,000 | - | - | - |
| Other Short Term Investments | $167,929,000 | $173,182,000 | $121,407,000 | $91,695,000 |
| Non Current Deferred Revenue | - | $0 | $2,509,000 | $13,147,000 |
| Current Deferred Revenue | - | $0 | $2,341,000 | $2,199,000 |
| Investments And Advances | - | - | $0 | $1,275,000 |
| Buildings And Improvements | - | - | - | $9,074,000 |
Fetched: 2026-06-01
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $6,728,000 | $-31,020,000 | $6,347,000 | $-180,691,000 |
| Operating Activities | ||||
| Operating Cash Flow | $6,728,000 | $-31,020,000 | $6,880,000 | $-180,092,000 |
| Cash Flow From Continuing Operating Activities | $6,728,000 | $-31,020,000 | $6,880,000 | $-180,092,000 |
| Investing Activities | ||||
| Investing Cash Flow | $8,829,000 | $-45,976,000 | $-25,522,000 | $175,288,000 |
| Cash Flow From Continuing Investing Activities | $8,829,000 | $-45,976,000 | $-25,522,000 | $175,288,000 |
| Capital Expenditure | - | - | $-533,000 | $-599,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-2,034,000 | $-1,443,000 | $230,000 | $-379,000 |
| Cash Flow From Continuing Financing Activities | $-2,034,000 | $-1,443,000 | $230,000 | $-379,000 |
| Net Other Financing Charges | $-2,174,000 | $-1,574,000 | $-1,982,000 | $-1,044,000 |
| Issuance Of Capital Stock | - | - | - | - |
| Net Common Stock Issuance | - | - | - | - |
| Common Stock Issuance | - | - | - | - |
| Other | ||||
| Income Tax Paid Supplemental Data | $1,000,000 | $3,982,000 | $2,367,000 | $1,782,000 |
| End Cash Position | $134,861,000 | $121,338,000 | $199,777,000 | $218,189,000 |
| Beginning Cash Position | $121,338,000 | $199,777,000 | $218,189,000 | $223,372,000 |
| Changes In Cash | $13,523,000 | $-78,439,000 | $-18,412,000 | $-5,183,000 |
| Proceeds From Stock Option Exercised | $140,000 | $131,000 | $2,212,000 | $665,000 |
| Net Investment Purchase And Sale | $8,829,000 | $-45,976,000 | $-24,989,000 | $175,887,000 |
| Sale Of Investment | $209,301,000 | $232,800,000 | $190,108,000 | $257,520,000 |
| Purchase Of Investment | $-200,472,000 | $-278,776,000 | $-215,097,000 | $-81,633,000 |
| Net Intangibles Purchase And Sale | $0 | $0 | $-509,000 | $-599,000 |
| Purchase Of Intangibles | $0 | $0 | $-509,000 | $-599,000 |
| Net PPE Purchase And Sale | $0 | $0 | $-24,000 | $0 |
| Purchase Of PPE | $0 | $0 | $-24,000 | $0 |
| Change In Working Capital | $32,207,000 | $36,174,000 | $51,077,000 | $-104,071,000 |
| Change In Other Current Liabilities | $-1,058,000 | $2,141,000 | $345,000 | $581,000 |
| Change In Other Current Assets | $158,000 | $147,000 | $-278,000 | $-2,000 |
| Change In Payables And Accrued Expense | $14,510,000 | $-76,987,000 | $-164,000 | $-102,729,000 |
| Change In Payable | $14,510,000 | $-76,987,000 | $-164,000 | $-102,729,000 |
| Change In Account Payable | $14,510,000 | $-76,987,000 | $-164,000 | $-102,729,000 |
| Change In Prepaid Assets | $-12,456,000 | $-934,000 | $7,874,000 | $2,860,000 |
| Change In Inventory | $34,878,000 | $105,443,000 | $56,121,000 | $-36,422,000 |
| Change In Receivables | $-3,825,000 | $11,214,000 | $-2,325,000 | $33,004,000 |
| Changes In Account Receivables | $-4,553,000 | $11,284,000 | $-2,573,000 | $32,663,000 |
| Stock Based Compensation | $13,937,000 | $17,705,000 | $15,646,000 | $26,213,000 |
| Amortization Of Securities | $-3,646,000 | $-5,729,000 | $-3,696,000 | $473,000 |
| Depreciation Amortization Depletion | $3,028,000 | $3,013,000 | $2,965,000 | $3,096,000 |
| Depreciation And Amortization | $3,028,000 | $3,013,000 | $2,965,000 | $3,096,000 |
| Amortization Cash Flow | $3,024,000 | $2,915,000 | $2,805,000 | $2,545,000 |
| Amortization Of Intangibles | $3,024,000 | $2,915,000 | $2,805,000 | $2,545,000 |
| Depreciation | $4,000 | $98,000 | $160,000 | $551,000 |
| Net Income From Continuing Operations | $-38,798,000 | $-82,183,000 | $-59,112,000 | $-105,803,000 |
| Change In Other Working Capital | - | $-4,850,000 | $-10,496,000 | $-1,363,000 |
| Repayment Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Change In Accrued Expense | - | - | - | $0 |
| Change In Interest Payable | - | - | - | $0 |
Fetched: 2026-06-01